Unique Mical1: Potential Drug Targets (G64780)

Target Name: MICAL1

NCBI ID: G64780

MICAL1

Unique Mical1: Potential Drug Targets

Mical1 (Nical) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of transmembrane protein (SMP), which includes proteins that span the cell membrane and extend into the cytoplasm. Mical1 is unique because it has a unique structure that allows it to interact with other proteins in the body.

One of the unique features of Mical1 is its ability to form aggregates with other SMP proteins. These aggregates, known as Mical1-containing domains, can interact with other SMP proteins and form complex structures that are involved in various cellular processes. This interaction between Mical1 and other SMP proteins is a key aspect of its function.

Mical1 has also been shown to play a role in the regulation of ion channels in the brain. It has been shown to interact with the protein known as NIMA, which is involved in the regulation of neurotransmitter release. This interaction between Mical1 and NIMA suggests that Mical1 may be a drug target for the treatment of neurotransmitter disorders.

In addition to its role in neurotransmission, Mical1 has also been shown to play a role in the regulation of inflammation. It has been shown to interact with the protein known as TLR2, which is involved in the regulation of inflammation. This interaction between Mical1 and TLR2 suggests that Mical1 may be a drug target for the treatment of inflammatory disorders.

Mical1 has also been shown to play a role in the regulation of cell survival. It has been shown to interact with the protein known as p53, which is involved in the regulation of DNA damage and cell survival. This interaction between Mical1 and p53 suggests that Mical1 may be a drug target for the treatment of diseases that are characterized by DNA damage and cell death.

In conclusion, Mical1 is a unique protein that has been shown to play a role in a variety of cellular processes. Its interaction with other SMP proteins and its ability to form aggregates with these proteins suggests that it may be a drug target for the treatment of a variety of disorders. Further research is needed to fully understand the function of Mical1 and its potential as a drug target.

Protein Name: Microtubule Associated Monooxygenase, Calponin And LIM Domain Containing 1

Functions: Monooxygenase that promotes depolymerization of F-actin by mediating oxidation of specific methionine residues on actin to form methionine-sulfoxide, resulting in actin filament disassembly and preventing repolymerization (PubMed:29343822). In the absence of actin, it also functions as a NADPH oxidase producing H(2)O(2) (PubMed:21864500, PubMed:26845023, PubMed:29343822). Acts as a cytoskeletal regulator that connects NEDD9 to intermediate filaments. Also acts as a negative regulator of apoptosis via its interaction with STK38 and STK38L; acts by antagonizing STK38 and STK38L activation by MST1/STK4. Involved in regulation of lamina-specific connectivity in the nervous system such as the development of lamina-restricted hippocampal connections. Through redox regulation of the actin cytoskeleton controls the intracellular distribution of secretory vesicles containing L1/neurofascin/NgCAM family proteins in neurons, thereby regulating their cell surface levels (By similarity). May act as Rab effector protein and play a role in vesicle trafficking

The "MICAL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MICAL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets